Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 12/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | WRN | Q14191 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21568272 | 0.92 | BLM (0.47) | BLMHSD17B10MEN1KMT2AWRN | |
| SCHEMBL21568276 | 0.91 | BLM (0.56) | BLMHSD17B10MEN1KMT2AWRN | |
| SCHEMBL23256590 | 0.89 | KCNQ3 (0.46) | BLMHSD17B10MEN1KMT2AWRN | |
| SCHEMBL21568229 | 0.87 | BLM (0.54) | BLMHSD17B10MEN1KMT2AWRN | |
| SCHEMBL21568374 | 0.87 | BLM (0.54) | BLMHSD17B10MEN1KMT2AWRN | |
| SCHEMBL23256591 | 0.87 | BLM (0.56) | BLMHSD17B10 | |
| SCHEMBL23256876 | 0.84 | MAPT (0.53) | BLMHSD17B10MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23256888 | 0.83 | NSD2 (0.53) | BLMHSD17B10MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21568084 | 0.83 | HSD17B10 (0.60) | BLMHSD17B10MEN1KMT2AHPGD | |
| SCHEMBL21568110 | 0.80 | CXCR2 (0.43) | HSD17B10MEN1KMT2AP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2019217509-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | BLM 619/4885HSD17B10 4412/4885MEN1 977/4885 |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | BLM 692/4885HSD17B10 4512/4885MEN1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.